Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449280 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00449280: Completed Phase 1 study, sponsored by University of Chicago.
NCT00449280 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00449280, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
Interventions
- DRUG Sorafenib
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00449280 record still lists
NCT00449280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00449280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00449280 about?
NCT00449280 is a clinical study titled "Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies". The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
What is the current status of trial NCT00449280?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00449280?
The interventions under investigation include: Sorafenib (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00449280?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00449280's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia